

Donald E Mager

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4716601/publications.pdf>

Version: 2024-02-01

141
papers

5,496
citations

108046

37
h-index

107981

68
g-index

143
all docs

143
docs citations

143
times ranked

6244
citing authors

#	ARTICLE	IF	CITATIONS
1	Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologics. <i>British Journal of Pharmacology</i> , 2022, 179, 4063-4077.	2.7	4
2	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. <i>Science Translational Medicine</i> , 2022, 14, eabg8402.	5.8	28
3	Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 370-384.	1.3	5
4	Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy. <i>Drugs in R and D</i> , 2021, 21, 189-202.	1.1	5
5	Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma. <i>AAPS Journal</i> , 2021, 23, 101.	2.2	2
6	Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics. <i>AAPS Journal</i> , 2021, 23, 110.	2.2	3
7	Platelet Transfusions Can Increase or Decrease the Inflammatory Response and Mortality in a Murine Model of Neonatal Polymicrobial Sepsis. <i>Blood</i> , 2021, 138, 2147-2147.	0.6	1
8	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. <i>Frontiers in Pharmacology</i> , 2021, 12, 817236.	1.6	6
9	Pharmacometrics and Systems Pharmacology 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 76-78.	2.3	18
10	Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. <i>BMC Cancer</i> , 2020, 20, 1024.	1.1	3
11	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 123, 1502-1512.	2.9	14
12	Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 77-90.	0.8	4
13	Rituximab dosing in hematological malignancies: an old question, revisited. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 661-666.	1.1	2
14	Pharmacodynamic Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1395-1406.	2.3	101
15	Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 732-740.	1.6	4
16	The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 516-529.	1.1	20
17	Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. <i>Pharmaceutical Research</i> , 2019, 36, 35.	1.7	17
18	Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 309-325.	1.0	50

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 146-157.	1.3	5
20	Fifty-Eight Years and Counting: High-Impact Publishing in Computational Pharmaceutical Sciences and Mechanism-Based Modeling. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2-7.	1.6	4
21	Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. <i>Clinical Cancer Research</i> , 2018, 24, 2631-2641.	3.2	52
22	Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 734-751.	1.3	9
23	Boolean network modeling in systems pharmacology. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 159-180.	0.8	60
24	Tacrolimus Population Pharmacokinetics and Multiple <i>CYP3A5</i> Genotypes in Black and White Renal Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1184-1195.	1.0	34
25	Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy. <i>Blood</i> , 2018, 132, 4037-4037.	0.6	0
26	Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. <i>Pharmaceutical Research</i> , 2017, 34, 668-679.	1.7	12
27	Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 956-965.	1.0	2
28	Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. <i>AAPS Journal</i> , 2017, 19, 487-496.	2.2	13
29	Quantitative systems toxicology. <i>Current Opinion in Toxicology</i> , 2017, 4, 79-87.	2.6	32
30	Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 756-764.	1.3	6
31	Influence of Meals and Glycemic Changes on QT Interval Dynamics. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 966-976.	1.0	19
32	A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. <i>AAPS Journal</i> , 2017, 19, 1436-1448.	2.2	17
33	Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. <i>MAbs</i> , 2017, 9, 15-28.	2.6	11
34	Population pharmacokinetics of exenatide. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 517-526.	1.1	22
35	Systems Pharmacology and Pharmacodynamics: An Introduction. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 3-14.	0.2	4
36	Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1561-1566.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 492-503.	5.7	4
38	Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 409-420.	1.1	4
39	Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1 α ,25-Dihydroxyvitamin D3 in Mice. <i>Drug Metabolism and Disposition</i> , 2016, 44, 189-208.	1.7	13
40	Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 115-125.	1.1	21
41	PKPD modelling to predict altered disposition of 1 α ,25-dihydroxyvitamin D ₃ in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation. <i>British Journal of Pharmacology</i> , 2015, 172, 3611-3626.	2.7	6
42	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 85-96.	1.1	14
43	The American Conference on Pharmacometrics 2015 (ACoP6). <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 1-2.	0.8	1
44	Soy Phosphatidylinositol Containing Nanoparticle Prolongs Hemostatic Activity of B-Domain Deleted Factor VIII in Hemophilia A Mice. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 388-395.	1.6	13
45	Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 541-552.	0.8	24
46	Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 448-458.	1.3	25
47	Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H68-H73.	1.5	6
48	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 67-75.	1.1	13
49	Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. <i>Pharmaceutics</i> , 2014, 6, 137-174.	2.0	81
50	Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. <i>Pharmaceutical Research</i> , 2014, 31, 35-45.	1.7	37
51	Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. <i>Pharmaceutical Research</i> , 2014, 31, 3265-3273.	1.7	24
52	Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 154-163.	1.1	7
53	Population-based meta-analysis of furosemide pharmacokinetics. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 119-133.	1.1	15
54	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1121-1129.	2.0	21

#	ARTICLE	IF	CITATIONS
55	Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. <i>Blood</i> , 2014, 123, 3381-3389.	0.6	58
56	Population Pharmacodynamic Modeling of Hyperglycemic Clamp and Meal Tolerance Tests in Patients with Type 2 Diabetes Mellitus. <i>AAPS Journal</i> , 2013, 15, 1051-1063.	2.2	1
57	Network-Based Approaches in Drug Discovery and Early Development. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 651-658.	2.3	82
58	Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 336-347.	1.1	8
59	Mechanisms of Subcutaneous Absorption of Rituximab in Rats. <i>Drug Metabolism and Disposition</i> , 2013, 41, 248-255.	1.7	41
60	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1159-1166.	2.0	29
61	Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics. <i>Pharmaceutical Research</i> , 2013, 30, 751-760.	1.7	29
62	Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 103-112.	1.3	27
63	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy- <i>N,N</i> -Dimethyltryptamine, and the Impact of CYP2D6 Status. <i>Drug Metabolism and Disposition</i> , 2013, 41, 975-986.	1.7	24
64	Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 527-539.	1.1	17
65	Population Pharmacodynamic Modeling of Exenatide After 2-Week Treatment in STZ/NA Diabetic Rats. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3844-3851.	1.6	13
66	Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2380-2394.	1.6	7
67	Dynamic Model of Platelet Lifespan in Adult and Newborn Mice. <i>FASEB Journal</i> , 2013, 27, 1b535.	0.2	0
68	Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics. <i>Cancer Research</i> , 2012, 72, 1632-1641.	0.4	30
69	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration-Time Curve in Hematopoietic Cell Transplantation Recipients. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1654-1664.	1.0	17
70	Merging Systems Biology with Pharmacodynamics. <i>Science Translational Medicine</i> , 2012, 4, 126ps7.	5.8	138
71	Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia. <i>Pharmaceutical Research</i> , 2012, 29, 2833-2844.	1.7	22
72	Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition. <i>Pharmaceutical Research</i> , 2012, 29, 2534-2542.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics and Pharmacodynamics of Anti-BR3 Monoclonal Antibody in Mice. <i>Pharmaceutical Research</i> , 2012, 29, 3180-3187.	1.7	1
74	Mechanisms of Tumor Vascular Priming by a Nanoparticulate Doxorubicin Formulation. <i>Pharmaceutical Research</i> , 2012, 29, 3312-3324.	1.7	14
75	Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 520-527.	2.3	42
76	Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 404-415.	1.0	2
77	Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 304-314.	1.1	109
78	Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. <i>Pharmaceutical Research</i> , 2012, 29, 490-499.	1.7	82
79	Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics. , 2012, , 285-302.		2
80	Quantitative structure- <i>pharmacokinetic</i> relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 63-77.	1.5	9
81	Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. <i>AAPS Journal</i> , 2011, 13, 265-273.	2.2	9
82	Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data. <i>AAPS Journal</i> , 2011, 13, 255-64.	2.2	23
83	Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 223-235.	0.8	2
84	Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 471-481.	1.1	36
85	Enantioselective pharmacokinetics of (<i>R</i>)- and (<i>S</i>)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. <i>Chirality</i> , 2011, 23, 138-143.	1.3	26
86	Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates. <i>Drug Delivery</i> , 2011, 18, 246-254.	2.5	8
87	Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems. <i>AAPS Journal</i> , 2010, 12, 1-10.	2.2	53
88	Quantitative structure-property relationships of camptothecins in humans. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 325-333.	1.1	5
89	Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 25-47.	0.8	77
90	Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. <i>Pharmaceutical Research</i> , 2010, 27, 920-932.	1.7	42

#	ARTICLE	IF	CITATIONS
91	Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon- β in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 327-332.	1.3	14
92	Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 479-488.	1.3	17
93	Bridging Pharmacology and Pathophysiology via Systems Modeling. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 56S-57S.	1.0	1
94	Role of P-Glycoprotein in Region-Specific Gastrointestinal Absorption of Talinolol in Rats. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1560-1566.	1.7	34
95	Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. <i>Diabetes Care</i> , 2010, 33, 1186-1192.	4.3	286
96	Pharmacokinetics and Toxicodynamics of Pralidoxime Effects on Paraoxon-Induced Respiratory Toxicity. <i>Toxicological Sciences</i> , 2010, 116, 660-672.	1.4	20
97	Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. <i>Pain Physician</i> , 2010, 13, 379-87.	0.3	40
98	Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 169-178.	1.3	23
99	Mechanisms of interferon- β effects on bone homeostasis. <i>Biochemical Pharmacology</i> , 2009, 77, 1757-1762.	2.0	37
100	Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 199-219.	0.8	25
101	Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol). <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1185-1195.	1.0	14
102	Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 16-24.	1.1	118
103	Phosphatidylserine Containing Liposomes Reduce Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A**Karthik Ramani and Razvan D. Miclea contributed equally to the manuscript.. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 1386-1398.	1.6	49
104	Development of Translational Pharmacokinetic-Pharmacodynamic Models. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 909-912.	2.3	109
105	Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 136-143.	2.3	18
106	Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 696-707.	1.0	39
107	Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2008, 47, 129-137.	1.6	37
108	Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 117-122.	1.0	58

#	ARTICLE	IF	CITATIONS
109	Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 555-562.	1.3	72
110	Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 423-430.	1.3	17
111	Analysis of Functional Signaling Domains from Fluorescence Imaging and the Two-Dimensional Continuous Wavelet Transform. <i>Biophysical Journal</i> , 2007, 93, 2900-2910.	0.2	11
112	HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 859, 213-221.	1.2	39
113	Partial derivative-Based sensitivity analysis of models describing target-mediated drug disposition. <i>AAPS Journal</i> , 2007, 9, E181-E189.	2.2	26
114	Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability. <i>Pharmaceutical Research</i> , 2007, 24, 1088-1097.	1.7	25
115	Quantitative structure-pharmacokinetic/pharmacodynamic relationships. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1326-1356.	6.6	74
116	Target-mediated drug disposition and dynamics. <i>Biochemical Pharmacology</i> , 2006, 72, 1-10.	2.0	220
117	Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats. <i>FASEB Journal</i> , 2006, 20, 631-637.	0.2	215
118	Mapping the Dose-Effect Relationship of Orbofiban from Sparse Data with an Artificial Neural Network. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2475-2486.	1.6	9
119	Pharmacokinetics and Pharmacodynamics of PEGylated IFN- γ 1a Following Subcutaneous Administration in Monkeys. <i>Pharmaceutical Research</i> , 2005, 22, 58-61.	1.7	39
120	Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition. <i>Pharmaceutical Research</i> , 2005, 22, 1589-1596.	1.7	190
121	Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model. <i>Clinical Cancer Research</i> , 2005, 11, 8856-8865.	3.2	60
122	Identification of Plasma Membrane Macro- and Microdomains from Wavelet Analysis of FRET Microscopy. <i>Biophysical Journal</i> , 2005, 88, 3625-3634.	0.2	9
123	EFFECTS OF PROTEIN CALORIE MALNUTRITION ON THE PHARMACOKINETICS OF KETAMINE IN RATS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 786-793.	1.7	30
124	PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 632-638.	1.7	114
125	Exendin-4 Pharmacodynamics: Insights from the Hyperglycemic Clamp Technique. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 830-835.	1.3	24
126	Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 1085-1092.	1.3	32

#	ARTICLE	IF	CITATIONS
127	Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 60-69.	2.3	14
128	Kullback-Leibler clustering of continuous wavelet transform measures of heart rate variability. <i>Biomedical Sciences Instrumentation</i> , 2004, 40, 337-42.	0.2	8
129	Integrated QSPRâ€™Pharmacodynamic Model of Genomic Effects of Several Corticosteroids. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 881-889.	1.6	17
130	Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 985-994.	1.6	54
131	Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1521-1525.	1.6	41
132	Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1438-1454.	1.6	4
133	Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-Î²1a in Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 262-270.	1.3	76
134	Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 969-976.	1.3	45
135	Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1216-1227.	1.0	132
136	Diversity of Mechanism-Based Pharmacodynamic Models. <i>Drug Metabolism and Disposition</i> , 2003, 31, 510-518.	1.7	318
137	Quantitative Structureâ€™Pharmacokinetic/Pharmacodynamic Relationships of Corticosteroids in Man. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2441-2451.	1.6	39
138	Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. <i>Pharmaceutical Research</i> , 2002, 19, 1537-1543.	1.7	55
139	General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2001, 28, 507-532.	0.8	501
140	Mechanistic Pharmacokinetic/Pharmacodynamic Models II. , 0, , 607-631.		3
141	Preclinical Pharmacokinetics. , 0, , 253-278.		1